

Claims:

- 1. A pharmaceutical composition comprising as active ingredients an anti-IgE antibody and at least one further antiallergic compound selected from the group consisting of anti-inflammatory agents, leukotriene modifiers, bronchodilators, antihistamines, interleukin antagonists, mast cell inhibitors, and immunotherapeutical agents, in which the active ingredients are present in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.**
- 2. The composition according to claim 1 wherein the anti-IgE antibody and the at least one further antiallergic compound are comprised in a single pharmaceutical formulation.**
- 3. The composition according to claims 1 or 2 wherein the anti-IgE antibody is Omalizumab.**
- 4. The composition according to claim 3, characterized in that Omalizumab is administered in a concentration dependent on the baseline IgE level of the patient to be treated.**
- 5. The composition according to any one of claims 1 to 4, characterized in that the combination comprises a further monoclonal antibody.**
- 6. The composition according to any one of claims 1 to 5, characterized in that the composition comprises at least one immunotherapeutical agent as the further pharmaceutically active compound.**
- 7. The composition according to claim 6, characterized in that the immunotherapeutical agent is a macrolide T-cell immunomodulator or immunosuppressant.**
- 8. The composition according to claim 7, characterized in that the macrolide T-cell immunomodulator or immunosuppressant is a FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor.**

9. The composition according to claim 8, characterized in that the FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor is an asco- or rapamycin.
10. The composition according to claim 9, characterized in that the ascomycin is 33-epichloro,33-desoxyascomycin (pimecrolimus).
11. The composition according to any one of claims 1 to 10, wherein the anti-IgE antibody is Omalizumab and the immunotherapeutical agent is 33-epichloro,33-desoxyascomycin (pimecrolimus).
12. The composition according to any one of claims 1 to 11, wherein the anti-IgE antibody and antiallergic compound are present in respective amounts which are jointly therapeutically effective against allergic disease.
13. The composition according to claim 12 wherein the anti-IgE antibody and antiallergic compound are present in respective amounts which are jointly therapeutically effective against asthma.
14. A method for the prevention, delay of progression or treatment of allergic disease comprising administering to a warm-blooded animal a therapeutically effective amount of a composition according to any one of claims 1 to 13.
15. A method of treatment of allergic disease comprising administering to a warm-blooded animal a therapeutically effective amount of an anti-IgE antibody and an antiallergic compound.
16. A method of treatment of allergic disease according to claim 15, wherein the anti-IgE antibody is Omalizumab.
17. A method of treatment of allergic disease according to claim 15 or 16, wherein the antiallergic compound comprises an immunotherapeutical agent.

18. A method of treatment of allergic disease according to claim 17, wherein the immunotherapeutical agent is a macrolide T-cell immunomodulator or immunosuppressant.
19. A method of treatment of allergic disease according to claim 18 wherein the macrolide T-cell immunomodulator or immunosuppressant is a FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor.
20. A method of treatment of allergic disease according to claim 19 wherein the FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor is an asco- or rapamycin.
21. A method of treatment of allergic disease according to claim 20 wherein the ascomycin is 33-epichloro,33-desoxyascomycin (pimecrolimus).
22. A method of treatment of allergic disease according to claim 15 wherein the anti-IgE antibody is Omalizumab and the immunotherapeutical agent is 33-epichloro,33-desoxyascomycin (pimecrolimus).
23. A method of treatment of allergic disease wherein an anti-IgE antibody and an antiallergic compound are co-administered.
24. A method of treatment of allergic disease wherein Omalizumab and 33-epichloro,33-desoxyascomycin (pimecrolimus) are co-administered.
25. A method of treatment of allergic disease according to claim 23 wherein Omalizumab is administered before 33-epichloro,33-desoxyascomycin (pimecrolimus).
26. The use of a composition according to any one of claims 1 to 13 in medicine.
27. The use of a composition according to any one of claims 1 to 13 for the manufacture of a medicament for the treatment of a warm-blooded animal having allergic disease.
28. Use of the composition according to any one of claims 1 to 13 for the prevention or treatment of allergic disease.

29. The use of Omalizumab and 33-epichloro,33-desoxyascomycin (pimecrolimus). for the manufacture of a medicament for the treatment of a warm-blooded animal having allergic disease.

30. The use of an antiallergic compound for the manufacture of a medicament for the treatment of a patient under treatment with Omalizumab.

31. The use of an antiallergic compound according to claim 30, wherein the antiallergic compound is an immunotherapeutical agent.

32. The use of an antiallergic compound according to claim 31, wherein the immunotherapeutical agent is a macrolide T-cell immunomodulator or immunosuppressant.

33. The use of an antiallergic compound according to claim 32, wherein the macrolide T-cell immunomodulator or immunosuppressant is a FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor.

34. The use of an antiallergic compound according to claim 33, wherein the FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor is an asco- or rapamycin.

35. The use of an immunotherapeutical agent according to claim 34, wherein the ascomycin is 33-epichloro,33-desoxyascomycin (pimecrolimus).

36. A kit comprising as active agent a composition according to any one of claims 1 to 13 together with instructions for simultaneous, separate or sequential use thereof in the prevention, delay of progression or treatment of allergic disease.